Comparing individual angiotensin-converting enzyme inhibitors with losartan in the risk of hospitalization for pneumonia and related mortality: A nationwide cohort study

Journal of Hypertension

Volumn 33, Issue 3, 2015, Pages 634-643

  Chang, Chia Hsuin ^a,b   Lin, Jou Wei ^a,b   Ruan, Sheng Yuan ^a,b   Lee, Yen Chieh ^a,c   Wu, Li Chiu ^a   Lin, Min Shung ^c   Lai, Mei Shu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

angiotensin receptor antagonists; angiotensin converting enzyme inhibitors; mortality; pneumonia

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; IMIDAPRIL; LISINOPRIL; LOSARTAN; PERINDOPRIL; RAMIPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; COHORT ANALYSIS; DOSE RESPONSE; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; AGED; COMPARATIVE STUDY; INCIDENCE; RISK; TAIWAN;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; COHORT STUDIES; ENALAPRIL; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; LOSARTAN; MALE; MIDDLE AGED; PNEUMONIA; RAMIPRIL; RISK; TAIWAN;

EID: 84922475017     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000438     Document Type: Article

References (32)

1. Eurostat. Causes of death statistics. http://epp.eurostat.ec.europa.eu/statistics-explained/index.php/Causes-of-death-statistics. [Last retrieved on 3 April 2014]
2. World Health Organization. The top 10 causes of death. http://who.int/mediacentre/factsheets/fs310/en/index.html. [Last retrieved on 3 April 2014]
3. Arnold FW, Wiemken TL, Peyrani P, Ramirez JA, Brock GN. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2013; 107:1101-1111
4. Heron M. Deaths: leading causes for 2010. Natl Vital Stat Rep 2013; 62:1-96
5. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for communityacquired pneumonia in adults in Europe: a literature review. Thorax 2013; 68:1057-1065
6. Sanz Herrero F, Blanquer Olivas J. Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med 2012; 33:220-231
7. Restrepo MI, Mortensen EM, Anzueto A. Common medications that increase the risk for developing community-acquired pneumonia. Curr Opin Infect Dis 2010; 23:145-151
8. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acidsuppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183:310-319
9. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 2009; 18:697-703
10. Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012; 55:1466-1473
11. Rafailidis PI, Matthaiou DK, Varbobitis I, Falagas ME. Use of ACE inhibitors and risk of community-acquired pneumonia: a review. Eur J Clin Pharmacol 2008; 64:565-573
12. Caldeira D, Alarcao J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. Br Med J 2012; 345:e4260
13. Arai T, Yasuda Y, Takaya T, Toshima S, Kashiki Y, Yoshimi N, et al. ACE inhibitors and symptomless dysphagia. Lancet 1998; 352:115-116
14. Sekizawa K, Matsui T, Nakagawa T, Nakayama K, Sasaki H. ACE inhibitors and pneumonia. Lancet 1998; 352:1069
15. Shinohara Y, Origasa H. Poststroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians. Adv Ther 2012; 29:900-912
16. Arai T, Yasuda Y, Takaya T, Toshima S, Kashiki Y, Shibayama M, et al. Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, and pneumonia in elderly hypertensive patients with stroke. Chest 2001; 119:660-661
17. Willenheimer R, Helmers C, Pantev E, Rydberg E, Lofdahl P, Gordon A. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol 2002; 85:261-270
18. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559
19. Lin JW, Chang CH, Caffrey JL, Wu LC, Lai MS. Examining the association of olmesartan and other Angiotensin receptor blockers with overall and cause-specific mortality. Hypertension 2014; 63:968-976
20. Kohl M, Pshreg H. A sas macro for proportional and nonproportional substribution hazards regression with competing risk data. http://cemsiis.Meduniwien.Ac.At/en/kb/science-research/software/statistica lsoftware/pshreg. [Last retrieved on 3 April 2014]
21. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15:291-303
22. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670-1676
23. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153
24. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041
25. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004; 169:1041-1045
26. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334:1649-1654
27. Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med 2010; 123:1016-1030
28. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999; 104:1693-1701
29. Arai T, Sekizawa K, Ohrui T, Fujiwara H, Yoshimi N, Matsuoka H, et al. ACE inhibitors and protection against pneumonia in elderly patients with stroke. Neurology 2005; 64:573-574
30. Ding PY, Hu OY, Pool PE, Liao W. Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensinconverting enzyme inhibitors? J Hum Hypertens 2000; 14:163-170
31. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-677
32. Gorouhi F, Khatami A, Davari P. A neglected issue in interpretation of results of randomized controlled trials: informative censoring. Dermatol Online J 2009; 15:13